Lanean...
Access to orphan drugs despite poor quality of clinical evidence
AIM: We analysed the Belgian reimbursement decisions of orphan drugs as compared with those of innovative drugs for more common but equally severe diseases, with special emphasis on the quality of clinical evidence. METHODS: Using the National Health Insurance Agency administrative database, we eval...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Blackwell Science Inc
2011
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3080635/ https://ncbi.nlm.nih.gov/pubmed/21395641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2010.03877.x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|